Diverse Genetic Study Identifies Thousands of Variants Impacting Drug Responses
New research reveals nearly every person carries genetic variations affecting how they process medications.
1Broad Genetic Diversity Analyzed
Researchers analyzed whole genome sequences from nearly 100,000 participants in the NIH All of Us program. By focusing on diverse ancestries historically excluded from biomedical research, the study identified thousands of previously unreported variants in 16 pharmacogenes. These genes dictate how the body metabolizes various prescription medications and therapies.
2Universal Genetic Variation Found
The study revealed that every single participant carried at least one genetic variant in the studied pharmacogenes. Approximately 99.5% of individuals possessed variants for which medical guidelines or the FDA recommend dosage adjustments or alternative drugs. This confirms that genetic influence on drug response is a universal human trait.
3Clinical Impact on Patients
Data indicates that one in four participants had already been prescribed a medication affected by their specific genetic profile. These variants influence the efficacy and safety of common drugs, including statins for cholesterol, stomach acid reducers like omeprazole, antidepressants, and blood thinners such as Plavix, potentially causing adverse side effects.
4Advancing Precision Medicine Goals
The findings published in Science Translational Medicine aim to move clinical care beyond the traditional trial-and-error approach. By mapping how DNA influences drug metabolism, researchers hope to enable personalized prescriptions. However, experts note that genetics is only one factor, alongside age and organ function, in determining patient outcomes.
5Barriers to Clinical Adoption
Despite the potential for improved care, significant hurdles remain before genetic testing becomes routine. Many patients lack access to genome sequencing, and physicians often remain unaware of how specific variants interact with common prescriptions. Furthermore, the complexity of managing a vast constellation of genetic variants complicates immediate clinical implementation.
6Funding Challenges Threaten Progress
The All of Us program faces severe financial constraints as funding from the 21st Century Cures Act expires in 2027. Projected budgets show an 80% decrease from 2023 peaks. These cuts have forced the program to scale back recruitment efforts, mobile enrollment units, and the sharing of genetic results with participants.
7Pediatric Research Stalled
Efforts to expand the dataset to include children, which began in 2023, have enrolled approximately 5,000 participants. However, these data are currently unavailable to researchers due to the ongoing funding crisis. Scaling this pediatric research is considered essential for the future of precision health but requires stable, long-term financial support.
8Future of Genomic Healthcare
While the study provides a robust foundation for pharmacogenomics, it does not yet prove that routine testing guarantees better clinical outcomes. Future success depends on securing stable funding to maintain the diversity of the database and translating these complex genetic findings into accessible, actionable tools for everyday medical practice.